TW201504246A - 巨環激酶抑制劑的固體劑型 - Google Patents
巨環激酶抑制劑的固體劑型 Download PDFInfo
- Publication number
- TW201504246A TW201504246A TW103122400A TW103122400A TW201504246A TW 201504246 A TW201504246 A TW 201504246A TW 103122400 A TW103122400 A TW 103122400A TW 103122400 A TW103122400 A TW 103122400A TW 201504246 A TW201504246 A TW 201504246A
- Authority
- TW
- Taiwan
- Prior art keywords
- ppm
- values
- crystalline
- acetic acid
- resonance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840703P | 2013-06-28 | 2013-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201504246A true TW201504246A (zh) | 2015-02-01 |
Family
ID=51136530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103122400A TW201504246A (zh) | 2013-06-28 | 2014-06-27 | 巨環激酶抑制劑的固體劑型 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637500B2 (enExample) |
| EP (1) | EP3013835B1 (enExample) |
| JP (1) | JP6110817B2 (enExample) |
| AR (1) | AR096759A1 (enExample) |
| CA (1) | CA2916605C (enExample) |
| ES (1) | ES2656189T3 (enExample) |
| TW (1) | TW201504246A (enExample) |
| WO (1) | WO2014207606A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111233833A (zh) * | 2018-11-28 | 2020-06-05 | 深圳市塔吉瑞生物医药有限公司 | 一种氘代大环化合物的制备方法 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| US10159663B2 (en) * | 2014-08-20 | 2018-12-25 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| US10420749B2 (en) | 2015-07-31 | 2019-09-24 | Pfizer Inc. | Crystalline form of lorlatinib free base |
| US20180282415A1 (en) | 2015-09-30 | 2018-10-04 | Merck Patent Gmbh | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer |
| WO2017148325A1 (zh) * | 2016-03-03 | 2017-09-08 | 深圳市塔吉瑞生物医药有限公司 | 一种大环化合物及包含该化合物的组合物 |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| MX2020003373A (es) * | 2017-10-10 | 2020-10-12 | Pfizer | Forma cristalina de hidrato de lorlatinib base libre. |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| WO2019209633A1 (en) | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109651398B (zh) * | 2019-01-25 | 2021-07-30 | 安庆多辉生物科技有限公司 | 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法 |
| EP3999514A1 (en) * | 2019-07-18 | 2022-05-25 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| PE20230608A1 (es) | 2020-05-05 | 2023-04-13 | Nuvalent Inc | Quimioterapicos de eter macrociclico heteroaromatico |
| WO2021226269A1 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CN112724077B (zh) * | 2020-12-29 | 2023-07-11 | 武汉利昌医药科技有限公司 | 一种劳拉替尼中间体的合成方法 |
| CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
| KR20240087788A (ko) | 2021-10-01 | 2024-06-19 | 뉴베일런트, 아이엔씨. | 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| CN104169286B (zh) | 2012-03-06 | 2016-06-08 | 辉瑞大药厂 | 用于治疗增殖性疾病的大环衍生物 |
-
2014
- 2014-06-17 CA CA2916605A patent/CA2916605C/en active Active
- 2014-06-17 EP EP14736454.1A patent/EP3013835B1/en not_active Not-in-force
- 2014-06-17 US US14/898,582 patent/US9637500B2/en active Active
- 2014-06-17 ES ES14736454.1T patent/ES2656189T3/es active Active
- 2014-06-17 WO PCT/IB2014/062296 patent/WO2014207606A1/en not_active Ceased
- 2014-06-18 JP JP2014124999A patent/JP6110817B2/ja not_active Expired - Fee Related
- 2014-06-26 AR ARP140102433A patent/AR096759A1/es unknown
- 2014-06-27 TW TW103122400A patent/TW201504246A/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111233833A (zh) * | 2018-11-28 | 2020-06-05 | 深圳市塔吉瑞生物医药有限公司 | 一种氘代大环化合物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3013835B1 (en) | 2017-12-13 |
| JP2015010091A (ja) | 2015-01-19 |
| WO2014207606A1 (en) | 2014-12-31 |
| CA2916605C (en) | 2018-04-24 |
| ES2656189T3 (es) | 2018-02-26 |
| AR096759A1 (es) | 2016-02-03 |
| EP3013835A1 (en) | 2016-05-04 |
| US9637500B2 (en) | 2017-05-02 |
| CA2916605A1 (en) | 2014-12-31 |
| US20160115178A1 (en) | 2016-04-28 |
| JP6110817B2 (ja) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201504246A (zh) | 巨環激酶抑制劑的固體劑型 | |
| US11020376B2 (en) | Crystalline form of lorlatinib free base | |
| CA3019905C (en) | Crystalline forms of lorlatinib maleate | |
| KR20210104808A (ko) | Tgfb 억제제의 신규한 다형체 형태 | |
| KR20100085142A (ko) | Ｃ-ｍｅｔ/ｈｇｆｒ 억제제의 다형체 | |
| JP2007277241A (ja) | （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの多形体 | |
| TW202328152A (zh) | 氮雜內醯胺化合物之晶型 |